Kidney cancer in 2017: Challenging and refining treatment paradigms

[1]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Plimack,et al.  Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Wolchok,et al.  Combination immunotherapy: a road map , 2017, Journal of Immunotherapy for Cancer.

[4]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[6]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[7]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[8]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[9]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[10]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.